Xiaoshan Hu

846 total citations
39 papers, 676 citations indexed

About

Xiaoshan Hu is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiaoshan Hu has authored 39 papers receiving a total of 676 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 18 papers in Cancer Research and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaoshan Hu's work include MicroRNA in disease regulation (11 papers), Cancer-related molecular mechanisms research (9 papers) and Circular RNAs in diseases (8 papers). Xiaoshan Hu is often cited by papers focused on MicroRNA in disease regulation (11 papers), Cancer-related molecular mechanisms research (9 papers) and Circular RNAs in diseases (8 papers). Xiaoshan Hu collaborates with scholars based in China, Italy and Canada. Xiaoshan Hu's co-authors include Shuping Han, Zhangbin Yu, Jingai Zhu, Chun Zhu, Shasha Zhu, Mengmeng Li, Lingmei Qian, Xirong Guo, Xuejie Wang and Xuehua Liu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Molecular and Cellular Biology.

In The Last Decade

Xiaoshan Hu

36 papers receiving 672 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaoshan Hu China 16 490 342 78 64 62 39 676
Yahui Shen China 15 355 0.7× 248 0.7× 70 0.9× 55 0.9× 39 0.6× 30 516
Shaoxin Huang China 13 346 0.7× 290 0.8× 38 0.5× 21 0.3× 91 1.5× 38 601
Jia Zhou China 10 246 0.5× 174 0.5× 54 0.7× 12 0.2× 26 0.4× 35 438
John Marentette United States 12 289 0.6× 117 0.3× 80 1.0× 17 0.3× 31 0.5× 27 540
Zhen He China 10 217 0.4× 97 0.3× 56 0.7× 17 0.3× 27 0.4× 25 454
Xiaolan Li China 13 171 0.3× 57 0.2× 66 0.8× 33 0.5× 42 0.7× 52 505
Marta Seco-Cervera Spain 16 306 0.6× 92 0.3× 43 0.6× 13 0.2× 43 0.7× 29 600
Miloš Lazić United States 10 390 0.8× 153 0.4× 258 3.3× 145 2.3× 12 0.2× 14 803
Yixin Su United States 14 240 0.5× 112 0.3× 18 0.2× 59 0.9× 57 0.9× 43 500
Chastain Anderson United States 10 413 0.8× 146 0.4× 38 0.5× 20 0.3× 47 0.8× 13 779

Countries citing papers authored by Xiaoshan Hu

Since Specialization
Citations

This map shows the geographic impact of Xiaoshan Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoshan Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoshan Hu more than expected).

Fields of papers citing papers by Xiaoshan Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoshan Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoshan Hu. The network helps show where Xiaoshan Hu may publish in the future.

Co-authorship network of co-authors of Xiaoshan Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoshan Hu. A scholar is included among the top collaborators of Xiaoshan Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoshan Hu. Xiaoshan Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Niu, Feiyu, Yan Yuan, Peng Jiang, et al.. (2024). Surufatinib monotherapy or combined with vinorelbine as a late-line therapy in patients with refractory advanced non–small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). e20543–e20543.
2.
Chen, Yanjie, Wenjuan Chen, Y. Sophia Dai, et al.. (2024). Human breast milk-derived phospholipid DOPE ameliorates intestinal injury associated with NEC by inhibiting ferroptosis. Food & Function. 15(21). 10811–10822. 1 indexed citations
3.
Hu, Xiaoshan, et al.. (2024). Senescence-related signatures predict prognosis and response to immunotherapy in colon cancer. Journal of Gastrointestinal Oncology. 15(3). 1020–1034. 3 indexed citations
4.
Hu, Xiaoshan, et al.. (2023). Incidence and Risk Factors for Retinopathy of Prematurity in a Tertiary Hospital in China. Clinical ophthalmology. Volume 17. 3189–3194. 2 indexed citations
5.
6.
Hu, Xiaoshan, et al.. (2022). 5-methylcytosine RNA methylation regulators affect prognosis and tumor microenvironment in lung adenocarcinoma. Annals of Translational Medicine. 10(5). 259–259. 24 indexed citations
7.
Hu, Xiaoshan, et al.. (2022). Novel cellular senescence-related risk model identified as the prognostic biomarkers for lung squamous cell carcinoma. Frontiers in Oncology. 12. 997702–997702. 4 indexed citations
8.
Hu, Xiaoshan, et al.. (2021). Molecular identification of an immunity- and Ferroptosis-related gene signature in non-small cell lung Cancer. BMC Cancer. 21(1). 783–783. 18 indexed citations
9.
Liu, Zichuan, et al.. (2021). Helicobacter pylori-induced protein tyrosine phosphatase receptor type C as a prognostic biomarker for gastric cancer. Journal of Gastrointestinal Oncology. 12(3). 1058–1073. 4 indexed citations
10.
Hu, Xiaoshan, et al.. (2021). Preoperative pectoralis muscle radiodensity as a risk factor for postoperative complications after thoracoscopic lobectomy for non-small cell lung cancer. Annals of Palliative Medicine. 10(5). 5444–5454. 2 indexed citations
11.
Li, Jingyun, et al.. (2020). MicroRNA-375 overexpression disrupts cardiac development of Zebrafish (Danio rerio) by targeting notch2. PROTOPLASMA. 257(5). 1309–1318. 13 indexed citations
12.
Hu, Xiaoshan, Heng Liu, Mengmeng Li, Jingai Zhu, & Zhangbin Yu. (2020). Transcriptomic analysis reveals the role of a peptide derived from CRYAB on the CoCl2-induced hypoxic HL-1 cardiomyocytes. Journal of Thrombosis and Thrombolysis. 51(2). 265–276. 2 indexed citations
13.
Gu, Meng, Wenjuan Tu, Jing Zhao, et al.. (2016). Circulating LncRNAs as Novel, Non-Invasive Biomarkers for Prenatal Detection of Fetal Congenital Heart Defects. Cellular Physiology and Biochemistry. 38(4). 1459–1471. 50 indexed citations
14.
Zhu, Shasha, Xiaoshan Hu, Zhangbin Yu, et al.. (2015). Effect of miR-20b on Apoptosis, Differentiation, the BMP Signaling Pathway and Mitochondrial Function in the P19 Cell Model of Cardiac Differentiation In Vitro. PLoS ONE. 10(4). e0123519–e0123519. 15 indexed citations
15.
Li, Mengmeng, Xiaoshan Hu, Jingai Zhu, et al.. (2014). Overexpression of miR-19b Impairs Cardiac Development in Zebrafish by Targeting ctnnb1. Cellular Physiology and Biochemistry. 33(6). 1988–2002. 31 indexed citations
16.
Li, Mengmeng, Xuejie Wang, Jingai Zhu, et al.. (2014). Toxic effects of polychlorinated biphenyls on cardiac development in zebrafish. Molecular Biology Reports. 41(12). 7973–7983. 24 indexed citations
17.
Liu, Xuehua, Liming Yang, Huiyan Wang, et al.. (2014). Effects of miR-19b knockdown on the cardiac differentiation of P19 mouse embryonic carcinoma cells. Molecular Medicine Reports. 11(4). 2504–2512. 11 indexed citations
18.
Wu, Xiangqi, Yunshan Cao, Junwei Nie, et al.. (2013). Genetic and Pharmacological Inhibition of Rheb1-mTORC1 Signaling Exerts Cardioprotection against Adverse Cardiac Remodeling in Mice. American Journal Of Pathology. 182(6). 2005–2014. 62 indexed citations
19.
Liu, Hailang, Guixian Song, Lijuan Zhou, et al.. (2013). Compared Analysis of LncRNA Expression Profiling inpdk1Gene Knockout Mice at Two Time Points. Cellular Physiology and Biochemistry. 32(5). 1497–1508. 26 indexed citations
20.
Zhu, Chun, Yulin Chen, Xuejie Wang, et al.. (2012). ShRNA-mediated gene silencing of AHR promotes the differentiation of P19 mouse embryonic carcinoma cells into cardiomyocytes. Molecular Medicine Reports. 6(3). 513–518. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yahui Shen Breakdown of academic impact, for papers by Shaoxin Huang Breakdown of academic impact, for papers by Jia Zhou Breakdown of academic impact, for papers by John Marentette Breakdown of academic impact, for papers by Zhen He Breakdown of academic impact, for papers by Xiaolan Li Breakdown of academic impact, for papers by Marta Seco-Cervera Breakdown of academic impact, for papers by Miloš Lazić Breakdown of academic impact, for papers by Yixin Su Breakdown of academic impact, for papers by Chastain Anderson
Rankless by CCL
2026